
    
      Subjects will be treated with vorinostat administered orally with daily dosing for 14 days of
      a 21-day treatment cycle in combination with niacinamide administered orally for 14 days in
      21-day treatment cycle and etoposide administered intravenously on days 8,9 and 10 of a
      21-day treatment cycle. Etoposide dose will be escalated until maximum tolerated dose (MTD)
      is determined.
    
  